Abstract: A method of treating and preventing secondary hyperparathyroidism in CKD by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering 25-hydroxyvitamin D3 with or without 25-hydroxyvitamin D2 and, as necessary, 1,25-dihydroxyvitamin D2 as a Vitamin D hormone replacement therapy.

Abstract: Methods and compositions for treating 25-hydroxyvitamin D insufficiency and deficiency in a patient are described herein. The method includes orally administering to the patient a delayed, sustained release formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3, or it includes gradually administering to the patient a sterile intravenous formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3.

Abstract: The present disclosure relates to molecules that function as selective modulators (i.e., inhibitors and agonists) of the Ras-homologous (Rho) family of small GTPases and, in particular, CDC42 GTPase, and their use to treat bacterial infection including systemic infection from sources such as Staphylococcus aureus and Streptococcus pyogenes.

Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.

Abstract: A method for treating NAFLD and/or NASH and suitable compositions for carrying out the method are claimed.

Abstract: A method for the treatment of hepatitis C infection genotype 1, 2, 4, 5, or 6, but not genotype 3 is provided comprising administering an effective amount of a combination of Compound (I), Compound (II), and Compound (III), or independently optionally their pharmaceutically acceptable salt, solvate or hydrate, optionally in a solid fixed dose composition.

Abstract: A method for the treatment of hepatitis C infection genotype 1, 2, 4, 5, or 6 is provided comprising administering an effective amount of a combination of Compound (I), Compound (II), and Compound (III), or independently optionally their pharmaceutically acceptable salt, solvate or hydrate, optionally in a solid fixed dose composition.

Abstract: Disclosed are pharmaceutical compositions comprising Compound I, having the formula: and an effective amount of sofosbuvir wherein the sofosbuvir is substantially crystalline. Also disclosed are methods of use for the pharmaceutical composition.

Abstract: The present invention relates to compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.

Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides encoding payloads for the treatment of CNS disorders.

Abstract: This disclosure relates to replication competent viral vectors for treating cell proliferative disorders. The disclosure further relates to the use of such replication competent viral vectors for delivery and expression of a heterologous nucleic acid in normal and diseased tissues and methods and compositions that facilitate such delivery and expression to tissues in vivo and in vitro. The disclosure further relates to replication competent retroviral vectors for these uses and in conjunction with methods and compositions that facilitate in vivo therapeutics.

Abstract: Disclosed herein is a method for promoting reduction of heat stress in animals, as well as a composition for use in the disclosed method. The composition comprises a glucan, silica, mineral clay, mannan, and optionally an endoglucanohydrolase, and may be administered to an animal that is susceptible to or suffers from heat stress.

Abstract: Disclosed herein is a solution, in particular a pharmaceutically acceptable solution, comprising icodextrin and hydroxyalkyl starch (HAS) that can be used in methods of preventing metastasis formation and/or relapse by administration to a body cavity of a subject afflicted with cancer. Also disclosed is a kit comprising icodextrin and HAS in pre-weighed amounts and a pharmaceutically acceptable means of dissolving the same. Also disclosed is a device comprising a pharmaceutically acceptable solution and means for administering the same.

Abstract: Bolaamphiphilic compounds are provided according to formula I: HG2-L1-HG1?? I where HG1, HG2 and L1 are as defined herein. Provided bolaamphilphilic compounds and the pharmaceutical compositions thereof are useful for delivering biologically active drugs into animal or human brain.

Abstract: A method for the treatment of bone marrow edema in a mammal comprising administering an effective amount of a polysulfated polysaccharide including salts thereof, to a mammal in need of such treatment.

Abstract: Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.

Abstract: Described are stable topical formulations useful in the treatment of viral infection, demodex infection and bacterial infection of the eye, and methods of using the compositions for treating viral infection, demodex infection and bacterial infection of the eye.

Abstract: A liposomal rehydration salt formulation comprising phosphatidylcholine liposomes, salts, water, and a percentage inclusion ratio of salts (salts retained within said liposomes/total salts) of at least 40%; and a process for preparing said formulation using tangential ultrafiltration.

Abstract: The present invention relies on the hitherto unrealised high affinity binding of ruthenium and indium to gastrins. Particularly, these metals can be bound directly to the gastrins under mild conditions and so can be used in treatment of conditions associated with elevated gastrin levels and in detection of tumours and other conditions where CCK receptors are over expressed.

Abstract: The present invention is directed to synthetic bactericidal compositions having clay like properties and a method of using these compositions to topically treat bacterially-caused skin infections and skin diseases. The compositions within the scope of the invention comprise a bactericidal effective amount of a reducing agent, such as pyrite, marcasite, pyrrhotite, FeS2, FeS, FeSO4—or other reducing agents having like properties, and a natural clay or clay mineral and/or synthetic clay or clay mineral, or other suitable materials having clay-like properties with a high (>10) or low (<5) pH. The synthetic bactericidal compositions are synthesized by adding the reducing agent to the either high (>10) or low (<5) pH clay or clay mineral. It is the presence of both the reducing agent and the high (>10) or low (<5) pH clay of said compositions which renders them bactericidal.

Abstract: The present invention provides methods for preparing modified blood clots comprising removal of the cellular content of the blood clots. The invention further provides uses of the modified blood clots as therapeutic agents and as delivery vehicles for cells, bio-molecules and other agents.

Abstract: The present invention provides purified blood plasma products from fraction II+III containing proteins at concentrations useful for the treatment of various diseases and infections including hepatitis B virus. Methods of manufacture and treatment are also provided. The purified blood plasma products regulate levels of immune cells and their proteins in the organs and peripheral blood of treated subjects. Examples of immune cells and associated proteins regulated by the purified blood plasma products include CD62L levels on T cells, CD4+, CD8+, CD28+, and Foxp3+ T cells, B cells, as well as granulocytes and macrophages.

Abstract: The invention refers to a decomposed platelet concentrate containing ?50% intact platelets and optionally ?200 pg/ml RANTES and specifically to its use in the prevention or treatment of hair loss and/or for promoting hair growth. The invention further refers to a composition comprising the decomposed platelet concentrate and body fat cells and the use of said composition for reconstructive and aesthetic and curative surgery and pain relief treatment.

Abstract: Provided herein are methods of treating a hematological disorder, a solid tumor, or an infectious disease in a subject in need thereof using natural killer cells in combination with a second agent, or using natural killer cells with genetic modifications for target specificity and/or homing specificity.

Abstract: Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

Abstract: Provided are a pharmaceutical composition for preventing or treating low back pain, the pharmaceutical composition including adipose tissue-derived mesenchymal stem cells and a hyaluronic acid derivative solution, and a method of preparing the same. Mesenchymal stem cells capable of differentiating into chondrocytes are mixed with a hyaluronic acid derivative solution prepared by using controlled reaction conditions of hyaluronic acid and hyaluronic acid derivative, for use as a composition for the prevention or treatment of diseases and low back pain caused by a change in degenerative change in intervertebral discs.

Abstract: The invention provides for compositions and methods for making and using adipose-derived stem cells for treating non-human mammals for various medical conditions.

Abstract: A method of enhancing the binding of growth factors and cell cultures to a demineralized allograft bone material which includes applying ex vivo an effective quantity of an ionic force change agent to at least a portion of the surface of a demineralized allograft bone material to produce a binding-sensitized demineralized allograft bone material and implanting the binding-sensitized demineralized allograft bone material into a host bone. The ionic force change agent may include at least one of enzymes, pressure, chemicals, heat, sheer force, oxygen plasma, supercritical nitrogen, supercritical carbon, supercritical water or a combination thereof. A molecule, a cell culture, or a combination thereof is administered to the binding-sensitized demineralized allograft bone material.

Abstract: Methods are provided for efficient production of midbrain dopaminergic (DA) neurons. In some aspects, methods involve differentiation and selection of DA neurons for a transgenic pluripotent cell population (e.g., cells comprising a selectable marker gene). Cell populations produced by the instant methods and methods of their use are likewise provided.

Abstract: The present invention relates to methods of repairing tissue. More specifically, the present invention relates to methods of using cells and an implantable support for the repair of tissue defects, where the implantable support and cells are implanted into the tissue defect less than 2 hours after the cells are applied to the support.

Abstract: The present disclosure relates to a method for producing a composition, wherein the method comprises the steps of co-culturing immortalized fibroblasts and immortalized keratinocytes, thereby producing secretion; separating the secretion from the fibroblasts and keratinocytes; and providing a pharmaceutically acceptable composition comprising the secretion. The present disclosure also relates to the composition obtainable by the method, wherein the composition preferably is a pharmaceutical composition for medical use, preferably for use in the treatment of a wound, preferably a chronic or acute wound.

Abstract: Methods for preparing capsules, such as micro- and/or nanocapsules from all-aqueous emulsions are described herein. The method includes mixing, combining, or contacting a first electrically charged phase containing a first solute with at least an optionally charged second phase containing a second solute. The solutes are incompatible with each other. The electrostatic forces between the two solutions induce the formation of droplets of a dispersed phase in a continuous phase. The droplets are then solidified to form the capsules.

Abstract: Compositions for oral administration to a young poultry bird, such as a chicken, that comprise cecal material from adult poultry birds and saline are disclosed. The compositions can be used to increase body weight gain in a poultry bird by administering them to a young bird by oral gavage. The compositions may also be used to increase feeding efficiency in a poultry bird. Further disclosed are compositions for application to poultry litter, for example, chicken litter, that are prepared using the cecal material from adult poultry bird. The compositions may be used to prevent or reduce colonization of the chicken gut by pathogenic bacteria. Also disclosed are method of selecting for bacterial strains with probiotic potential.

Abstract: Described herein are avian follistatin products, and methods for producing such products, in which such products are effective for a variety of conditions, including increasing muscle mass. Avian follistatin products described herein are packaged as dietary supplements or nutritional supplements are useful in muscle regeneration.

Abstract: Synergistic composition comprising propolis and carnosic acid for use in the prevention and treatment of candidiasis. The invention relates to a synergistic composition comprising propolis that comprises polyphenols at a concentration between 70 and 90% by weight of propolis and carnosic acid, for use in the prevention and treatment of candidiasis in humans and/or animals. The invention also relates to a synergistic pharmaceutical and/or veterinary composition and a synergistic food product.

Abstract: This document provides methods and materials related to Prevotella histicola preparations. For example, Prevotella histicola preparations in the form of an oral medicament or dietary supplement (e.g., a pill, tablet, capsule) are provided. In addition, methods and materials for using a Prevotella histicola preparation provided herein as an anti-inflammatory agent are provided.

Abstract: This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of diabetes (particularly Type 2 diabetes), obesity and related conditions, metabolic syndrome, insulin resistance, and impaired glucose metabolism and consequences thereof, lowering tissue inflammation, treating hepatitis, myositis and cardiovascular conditions.

Abstract: An algal biomass and supernatant derived from at least one species of algae exhibits anti-inflammatory and immune response modulating properties. Methods of reducing the symptoms of or treating a condition or disease in an animal, including bovine mastitis and Bovine Respiratory Disease Complex, and the pain and discomfort caused by osteoarthritis, injury or overexertion or muscle and connective tissue strains, comprises administering to the animal in need thereof an algal biomass or supernatant derived from at least one species of algae, or an extract, derivative or biologically active compound derived from the algae species, biomass or supernatant, or compositions thereof.

Abstract: The present invention provides an egg-laying rate-improving agent for egg-laying hens, quails, or broiler breeders, the egg-laying rate-improving agent being characterized by comprising unheated cashew nut shell liquid, heated cashew nut shell liquid, anacardic acid, cardanol, and/or cardol.

Abstract: The present invention relates to extracts derived from plants and/or fractions thereof, compositions comprising same and use thereof in protecting tissues from damages caused by exogenous toxins. In particular, the present invention relates to polar extract and/or fraction thereof derived from Asteriscus graveolens, compositions comprising same and use thereof in protecting tissues comprising epithelial cell from the deleterious effect of exogenous toxins, particularly toxins originating from environmental pollution.

Abstract: Disclosed are a eucommia leaf extract, and preparation method and use thereof. The extract is a liquid of the eucommia leaf or an ethyl alcohol extract, and has chlorogenic acid of a content not less than 9%, geniposidic acid of a content not less than 1% and aucubin of a content not less than 1%. The extract has a good effect on psoriasis.

Abstract: A composition and method for treating itching, burning and discomfort of the skin and/or mucous membranes including the perianal and vaginal regions. The composition comprising therapeutically effective amounts of Aloe barbadensis leaf gel, deionized water, C12-15 alkyl benzoate, Camellia sinensis leaf extract, ceteareth-20, cetearyl alcohol, cetyl alcohol, ethylhexylglycerin, glycerin stearate, Hamamelis virginiana extract, Helianthus annus seed oil, PEG-100 stearate, petrolatum, phenoxyethanol, stearyl alcohol, tocopheryl acetate, Zemea propanediol and hydrocortisone.

Abstract: A method for enhancing at least one of alertness, attention, concentration and memory in a person in need thereof, comprising administering a composition to said person, said composition comprising: a) an effective amount of an extract of Cyperus esculentus peel, Cyperus esculentus rhizomes, or a combination thereof; b) an effective amount of mangiferin, norathyriol, or an extract comprising mangiferin or norathyriol; or c) a synergistic combination of (a) and (b).

Abstract: The invention provides a fermented Pennisetum extract, which has an advantageous effect in treating and preventing a cancer without toxicity to normal cells. The invention also provides a process of preparing the fermented Pennisetum extract and the application of the fermented Pennisetum extract in the treatment or prevention of a cancer.

Abstract: The present invention relates to the technical field of health care products, in particular to a composition and use thereof in the manufacture of a product for improving intestinal function. The present invention provides a composition and use thereof in the manufacture of a product for improving intestinal function. In the present invention, probiotics, prebiotics, Crataegi Fructus and Dioscoreae Rhizoma are reasonably compounded, wherein each component acts synergistically, thus allowing the obtained composition to have good effects of preventing and/or treating diarrhea as well as improving intestinal flora. The efficacy thereof is significantly superior to (P<0.05) that of the Comparative Examples.

Abstract: Princess lite is a cream used to treat and manage breast health. It has been effective in dissolving cyst and tumors, benign and malignant, in the breast and other parts of the body. It begins working on first use. It is most effective when used together with heat therapy at least 1½-2 hours daily on inflicted site. It dissolved within a two month period; however, it began minimizing the tumors immediately. The garlic helps fight off virus and bacterial infections. The coconut oil increases your energy, boost your metabolism, supports immune health, promotes antiviral, antifungal, and antibacterial activity. Castor oil is a natural laxative, it benefits lymphatic system increasing the production of lymphocytes and helping to remove toxins from the body. Pau D'Arco is to fight infection and is used to treat various forms of cancer.

Abstract: Pre-implantation factor (PIF) may be used to treat intracellular damage. Aspects of the invention are directed to a method of treating intracellular damage comprising administering PIF to a subject in need thereof. Some aspects may be directed to methods of increasing cytokine secretion in response to intracellular damage comprising administering PIF to a subject in need thereof. The intracellular damage may be a result of a disease such as Listeria monocytogenes infection, malaria, Lyme disease, cardiovascular disease, duodenal peptic ulcer, atherosclerosis, peritonitis or tuberculosis. In some aspects, a method of treating tuberculosis is disclosed, comprising administering PIF to a subject in need thereof. In some aspects, a method of treating atherosclerosis is disclosed, comprising administering PIF to a subject in need thereof. In some aspects, a method of treating peritonitis is disclosed, comprising administering PIF to a subject in need thereof.

Abstract: The present invention provides polypeptide modulators of complement activity, including cyclic polypeptide modulators. Also provided are methods of utilizing such modulators as therapeutics.

Abstract: The present invention relates to a combination comprising a proteasome inhibitor and a cyclic peptide that comprises an exposed Arg-Gly-Asp (RGD) moiety. In particular, the present invention relates to a combination comprising a proteasome inhibitor selected from the group consisting of: a boronate, an epoxyketone, a peptide aldehyde and a ?-lactone protease inhibitor; and a cyclic peptide that comprises an exposed Arg-Gly-Asp (RGD) moiety. More particularly, the present invention relates to a combination comprising a proteasome inhibitor selected from the group consisting of: bortezomib, delanzomib, ixazomib, carfilzomib, oprozomib, MG132 and marizomib; and a cyclic peptide that comprises an exposed Arg-Gly-Asp (RGD) moiety.

Abstract: Provided are methods and compositions for treating an ocular disease associated with increased intraocular pressure using a therapeutically effective amount of receptor associated protein (RAP), a derivative of RAP, a variant of RAP, or a fragment of RAP. Also provided are methods and compositions for reducing intraocular pressure.